ArticleNature microbiology2025
ESKAPE pathogens rapidly develop resistance against antibiotics in development in vitro.
Article in Nature microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- Non-Traditional Antibacterial Agents Relevant to the WHO 2024 Priority Pathogens: A Structured Update of the Clinical Pipeline.Antibiotics (Basel, Switzerland) · 2026Review
- Neglected ESKAPE Pathogens in Companion Animals: Diagnostic Bias, Zoonotic Blind Spots, and Phytotherapeutic Opportunities.Pathogens (Basel, Switzerland) · 2026Review
- Article
- Structure-Function Regulation of Proteolytically Stable Amphiphilic Peptide-Based Soft Materials With Antimicrobial Efficacy Against Drug-Resistant Strains and Anticancer Activity in Triple-Negative Breast Cancer Cells.Chembiochem : a European journal of chemical biology · 2026Article
- Plant-Derived Compounds as Antibiotic Adjuvants Against Drug-Resistant ESKAPE Pathogens: Mechanisms of Action, Synergistic Strategies, and Translational Challenges.Antibiotics (Basel, Switzerland) · 2026Review
- ECLIPSE: exploring the dark proteome of ESKAPE pathogens through the sequence similarity network of the Protein Universe Atlas.Bioinformatics (Oxford, England) · 2026Article
- Bioactive Compounds from Mangrove-Associated Fungi as Leads Against ESKAPE Pathogens.Life (Basel, Switzerland) · 2026Review
- Rapid Multiplex Antimicrobial Resistance Profiling and Bacterial Identification by LAP-MALDI Mass Spectrometry Biotyping.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Comparison of the Effect of Silver Nanoparticles Biosynthesized withPharmaceutics · 2026Article
- Whole-genome sequences of Enterobacter cloacae H5 and Enterobacter bugandensis H6 isolated from patients in Khartoum State, Sudan.BMC genomic data · 2026Article
- Antimicrobial Resistance as a Global Public Health Challenge: Epidemiological Burden, Bioethical Dimensions and Emerging Therapeutic Strategies.Infectious disease reports · 2026Review
- Antimicrobial resistance profiles of ESKAPE pathogens isolated in a microbiology laboratory in Somalia: a two-year retrospective study.BMC infectious diseases · 2026Article
- Biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa in cheese production systems.Scientific reports · 2026Article
- Harnessing artificial intelligence for antimicrobial discovery and optimization.Current opinion in microbiology · 2026Review
- The ESKAPE Challenge: Understanding Resistance and Exploring Alternative Treatments.Antibiotics (Basel, Switzerland) · 2026Review
- In vitro and in vivo activity of colistin-nitroxoline combination against polymyxin heteroresistant carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2026Article
- An ATP-Mediated Antibiotic β-Peptide Nanofiber That Kills Multidrug-Resistant Bacteria via a Multistage Mechanism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ciprofloxacin resistance enhances biofilm formation and modulates virulence in Acinetobacter baumannii: Insights into the role of efflux pumps and quorum sensing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Targeting Resistance Vulnerabilities of Clinical ESKAPE Isolates Using Lactoferrin and Its Functional Fragments.Current microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite ongoing antibiotic development, evolution of resistance may render candidate antibiotics ineffective. Here we studied in vitro emergence of resistance to 13 antibiotics introduced after 2017 or currently in development, compared with in-use antibiotics. Laboratory evolution showed that clinically relevant resistance arises within 60 days of antibiotic exposure in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa, priority Gram-negative ESKAPE pathogens. Resistance mutations are already present in natural populations of pathogens, indicating that resistance in nature can emerge through selection of pre-existing bacterial variants. Functional metagenomics showed that mobile resistance genes to antibiotic candidates are prevalent in clinical bacterial isolates, soil and human gut microbiomes. Overall, antibiotic candidates show similar susceptibility to resistance development as antibiotics currently in use, and the corresponding resistance mechanisms overlap. However, certain combinations of antibiotics and bacterial strains were less prone to developing resistance, revealing potential narrow-spectrum antibacterial therapies that could remain effective. Finally, we develop criteria to guide efforts in developing effective antibiotic candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.